Brief: Kinnate Doses First Patient In Phase 1 Clinical Trial Of FGFR Inhibitor Product Candidate
18/04/2022 13:41
April 18 (Reuters) - Kinnate Biopharma Inc KNTE.O :
* KINNATE BIOPHARMA INC. ANNOUNCES FIRST PATIENT DOSED IN
PHASE 1
CLINICAL TRIAL OF ITS FGFR INHIBITOR PRODUCT CANDIDATE, KIN-3248
Source text for Eikon: ID:nGNX75xpbG
Further company coverage: KNTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kinnate Biopharma
See all newsKinnate Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: XOMA Announces Calculation Of Additional Price Per Share And Extension Of Expiration Date For Tender Offer For Kinnate Biopharma Inc
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview